Vetter wins the prestigious Red Dot Design Concept Award with V-OVS®

© Vetter Pharma International GmbH: V-OVS® next

– Award recognizes forward-looking design concept
– New syringe closure system builds on more than two decades of successful market experience

Vetter, one of the world's leading pharmaceutical service providers for the aseptic manufacturing of injectable medicines, has been awarded the Red Dot Award in the "Design Concept" category for its new syringe closure system V-OVS® next. The internationally recognized award honors groundbreaking product concepts distinguished by innovation, functionality, and outstanding design. The accolade underscores Vetter's commitment to developing closure systems that improve usability on one hand and meet the growing demands of pharmaceutical and biotechnology companies on the other. Numerous design improvements enhance safety, ease of use, and compatibility with different syringe formats. This sets new standards for Luer-lock syringe closures.

"We are very pleased about the V-OVS® next award with the Red Dot," says Dr. Claus Feußner, Senior Vice President Development Service at Vetter. "This result demonstrates how we successfully combine technological innovation with the needs of users. Our goal was to develop a closure system that enhances functionality and patient safety while being intuitive to operate, creating real added value."

Safety and user-friendliness at the core

A key feature of the system is the robust locking mechanism. It ensures a secure connection between the syringe and the closure and reduces the risk of unintentional rotation. Additionally, V-OVS® next features an originality seal that irreversibly breaks upon first opening, increasing safety and product integrity.

Ease of use also played a crucial role in development. Ergonomically designed grip elements intuitively show users the correct gripping points. Integrated arrows further facilitate the opening process. The design combines functionality with a high-quality appearance, providing pharmaceutical and biotech companies with additional opportunities to visibly differentiate their products in an increasingly competitive market environment.